Ravulizumab - Alexion Pharmaceuticals

Drug Profile

Ravulizumab - Alexion Pharmaceuticals

Alternative Names: ALXN 1210

Latest Information Update: 31 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alexion Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Phase I Immunological disorders

Most Recent Events

  • 15 Mar 2018 Efficacy and adverse events data from a phase III trial in Paroxysmal nocturnal haemoglobinuria released by Alexion Pharmaceuticals
  • 15 Mar 2018 Alexion Pharmaceuticals initiates an extension study of a phase III trial in Paroxysmal nocturnal haemoglobinuria
  • 15 Mar 2018 Alexion Pharmaceuticals plans clinical development for Myasthenia gravis and IgA nephropathy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top